The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study
Open accessAbstract
Here we studied plasma metabolomic profiles as determinants of progression to ESRD in patients with Type 2 diabetes (T2D). This nested case-control study evaluated 40 cases who progressed to ESRD during 8-12 years of follow-up and 40 controls who remained alive without ESRD from the Joslin Kidney Study cohort. Controls were matched with cases for baseline clinical characteristics; although controls had slightly higher eGFR and lower levels of urinary albumin excretion than T2D cases. Plasma metabolites at baseline were measured by mass spectrometry-based global metabolomic profiling. Of the named metabolites in the library, 262 were detected in at least 80% of the study patients. The metabolomic platform recognized 78 metabolites previously reported to be elevated in ESRD (uremic solutes). Sixteen were already elevated in the baseline plasma of our cases years before ESRD developed. Other uremic solutes were either not different or not commonly detectable. Essential amino acids and their derivatives were significantly depleted in the cases, whereas certain amino acid-derived acylcarnitines were increased. All findings remained statistically significant after adjustment for differences between study groups in albumin excretion rate, eGFR or HbA1c. Uremic solute differences were confirmed by quantitative measurements. Thus, abnormal plasma concentrations of putative uremic solutes and essential amino acids either contribute to progression to ESRD or are a manifestation of an early stage(s) of the disease process that leads to ESRD in T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Statistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692
Host-gut microbiota metabolic interactions
Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., & Pettersson, S. (2012) · Science · doi:10.1126/science.1223813 · Cited by 4,760
Metabolite profiles and the risk of developing diabetes
Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., McCabe, E., Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2307 · Cited by 3,143
Ohta, T., Masutomi, N., Tsutsui, N., Sakairi, T., Mitchell, M., Milburn, M. V., Ryals, J. A., Beebe, K. D., & Guo, L. (2009) · Toxicologic Pathology · doi:10.1177/0192623309336152 · Cited by 213 · cited 2×
“(5, 6) The detailed protocols of global metabolomics profiling are provided in the Supplementary information.”
BackgroundFloegel, A., Drogan, D., Wang-Sattler, R., Prehn, C., Illig, T., Adamski, J., Joost, H.-G., Boeing, H., & Pischon, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021103 · Cited by 135 · cited 2×
“…persistent, defined here as “stable” and of particular interest, which remains in accordance with the systematic report by Floegel et al. (27) Fold differences between the mean plasma concentration in progressors to ESRD and non-progressors were analyzed for the 262 common metabolites…”
MethodSerum Metabolite Concentrations and Decreased GFR in the General Population
Goek, O.-N., Döring, A., Gieger, C., Heier, M., Koenig, W., Prehn, C., Römisch-Margl, W., Wang-Sattler, R., Illig, T., Suhre, K., et al. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.01.014 · Cited by 121 · cited 2×
“(73) Serum acylcarnitines deriving from lipid and amino acids are inversely correlated with GFR in individuals with normal as well as with impaired renal function.(18, 74, 75) Acylcarnitines transport is regulated by organic carnitine transporters in the kidney.”
Background
Cited by
Metabolomics: A New Tool to Reveal the Nature of Diabetic Kidney Disease
Huang, G., Li, M., Li, Y., & Mao, Y. (2022) · Laboratory Medicine · doi:10.1093/labmed/lmac041 · Cited by 922
Targeting metabolic dysregulation for fibrosis therapy
Zhao, X., Kwan, J. Y. Y., Yip, K., Liu, P. P., & Liu, F.-F. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0040-5 · Cited by 513
Molecular pathways that drive diabetic kidney disease
Mohandes, S., Doke, T., Hu, H., Mukhi, D., Dhillon, P., & Susztak, K. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165654 · Cited by 341
Diagnosis of diabetic kidney disease: state of the art and future perspective
Persson, F., & Rossing, P. (2018) · Kidney International Supplements · doi:10.1016/j.kisu.2017.10.003 · Cited by 335
Evenepoel, P., Poesen, R., & Meijers, B. (2017) · Pediatric Nephrology · doi:10.1007/s00467-016-3527-x · Cited by 305
Metadata
- Authors
- Niewczas, M. A., Sirich, T. L., Mathew, A. V., Skupien, J., Mohney, R. P., Warram, J. H., Smiles, A., Huang, X., Walker, W., Byun, J., Karoly, E. D., Kensicki, E. M., Berry, G. T., Bonventre, J. V., Pennathur, S., Meyer, T. W., & Krolewski, A. S.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 85
- Issue
- 5
- Pages
- 1214-1224
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2027852347
- Cited by
- 225
- References
- 7
- FWCI
- 14.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. https://app.cochat.ai/papers/10.1038/ki.2013.497
- The paper
- Niewczas, M. A., Sirich, T. L., Mathew, A. V., Skupien, J., Mohney, R. P., Warram, J. H., Smiles, A., Huang, X., Walker, W., Byun, J., Karoly, E. D., Kensicki, E. M., Berry, G. T., Bonventre, J. V., Pennathur, S., Meyer, T. W., & Krolewski, A. S. (2014). Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney International. https://doi.org/10.1038/ki.2013.497
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.